Xilio Therapeutics Profit Margin

The latest profit margin for XLO is -28.07% as of March 2026. That compares with -141.18% in the prior-year period — up 80.1% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Xilio Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, XLO's profit margin moved from -141.18% to -28.07% — a 80.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xilio Therapeutics's valuation or profitability profile.

Against Healthcare companies, XLO currently prints -28.07% for profit margin, while the sector average sits near 15.29%. That is roughly 283.5% below the sector mean. Large gaps often invite a closer look at Xilio Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Xilio Therapeutics converts resources into returns. At -28.07%, XLO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -141.18% in the prior-year period — up 80.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XLO's profit margin (-28.07%), review year-over-year change from -141.18%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.